Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
90
resultados
Última actualización
04/11/2026 [08:05:00]
Resumen de: MD1994Y
The invention relates to medicine, in particular to phthisiology and pulmonology, clinical immunology, allergology and pathophysiology, and can be used for diagnosing pulmonary tuberculosis in combination with certain viral infections in patients with secondary immunodeficiency.Summary of the invention consists in that an immunological study of peripheral blood is performed with the determination of the following indicators: the number of lymphocytes, the functional activity of lymphocytes in the test using the transformation reaction of lymphocyte blasts with phytohemagglutinin, the glucose consumption from the supernatant obtained from the cultivation of lymphocytes in the test using the transformation reaction of lymphocyte blasts with phytohemagglutinin, the activity of lactate dehydrogenase and lymphocyte aldolase, and if the results of the determined indicators show a deficit within <1/3 compared to the indicators in practically healthy sunjects, monoinfection with tuberculosis is diagnosed; if the results of the indicators show a deficit of 1/3…2/3 compared to the indicators in practically healthy subjects, the combination of tuberculosis with infection with the human immunodeficiency virus is diagnosed; and if the results of the indicators show a deficit of >2/3 compared to the indicators in practically healthy subjects, the combination of tuberculosis with human immunodeficiency virus infection and COVID-19 is diagnosed.
Resumen de: US20260335274A1
Pharmaceutical formulations for nasal administration are disclosed. The pharmaceutical formulation contains a green tea catechin derivative (such as an epigallocatechin-3-gallate-palmitate); and preferably further includes a carbohydrate (such as a polysaccharide); and a pharmaceutically acceptable carrier. The pharmaceutical formulation has a viscosity sufficient to maintain the green tea catechin derivative in contact with nasal epithelial cells optionally for at least about 30 minutes in the presence of mucus. Also described are methods of using the nasal formulations for preventing, reducing, and/or treating neurological damages caused by exposure to a virus, such as a SARS-CoV-2. For example, the disclosed pharmaceutical formulations can treat or prevent one or more symptoms of long COVID in an infected subject, and/or repair the damaged nasal epithelial cells, neuroepithelial cells, vascular cells, and/or neurons and restore their functions in a subject recovered from a COVID infection, such as the olfactory function of these cells.
Resumen de: US20260337527A1
The present invention relates to a non-woven fabric, a method for producing a non-woven fabric, a wipe or tissue and uses thereof as well as a disinfecting method, in particular against bacteria and viruses, such as coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The non-woven fabric comprises pulp fibers and/or cellulosic fibers, a binder, a cationic polymer, and a disinfecting agent.
Resumen de: US20260335432A1
Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.
Resumen de: US20260335895A1
A ferrofluidic fluid assay device uses swarm of millimeter-sized magnets was employed as mobile robotic agents (“ferrobots”) for precise and robust handling of magnetized sample droplets and high-fidelity delivery of flexible assay workflows. Within a palm-sized printed circuit board-based programmable platform a myriad of sample handling and bioanalytical operations involved in pooled testing can be performed. This automated technology was applied using the loop-mediated isothermal amplification and detection of SARS-COV-2 virus in clinical samples, where the test results completely matched those obtained off-chip. This technology is easily manufacturable and distributable, and its adoption for viral testing could lead to a 10 to 300-fold reduction in reagent costs, and three orders of magnitude reduction in instrumentation cost. Multiplexed assays may also be performed on a single device.
Resumen de: US20260335429A1
It is provided a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2′-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome.
Resumen de: US20260337187A1
The present disclosure relates to the use of compounds such as compounds of Formula I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, disorders or conditions such as diseases, disorders or conditions treatable by inhibiting SWAP-70 and/or treatable by inhibiting neutrophil reactive oxygen species (ROS) production, neutrophil NETosis, B lymphocyte plasmablast development, B lymphocyte IgE production, mast cell degranulation, eosinophil ROS production, mast cell cytokine release, B lymphocyte cytokine release, endothelial cell cytokine release, endothelial cell-immune cell interactions, and/or macrophage/monocyte migration, such as treatment of lung inflammation induced by viruses such as SARS-CoV-2:
Resumen de: WO2026226538A1
Described herein are systems, methods, and kits for predicting post-acute sequelae of a viral infection in a subject. The disclosed methods may comprise obtaining a biological sample from the subject during an acute phase of the viral infection, measuring a level of at least one interferon stimulated gene protein in the biological sample, and determining a risk of the subject developing post-acute sequelae based on the measured level of the at least one interferon stimulated gene protein. In some embodiments, the viral infection is a SARS-CoV-2 infection. Also described herein are methods for treating or preventing post-acute sequelae of a viral infection in a subject in need thereof.
Resumen de: WO2026225881A1
The present invention relates to an amplification-free universal detection technique using Cas12a2 and multiple crRNAs. The present invention provides a technique capable of detecting target RNA without separate nucleic acid amplification by utilizing Cas12a2 and multiple crRNAs. In particular, the present invention can universally detect SARS-CoV-2 variants at or below the attomole level with very high specificity and sensitivity. That is, the method according to the present invention has the advantage of being able to maintain consistent diagnostic performance despite the evolution of SARS-CoV-2.
Resumen de: WO2026224730A1
Most of the vaccines developed against SARS-CoV-2 are based on structural proteins of the virus, especially the spike protein. Antibody dependent enhancement of infection is a common hurdle that comes in the way of vaccine development when structural proteins are used. As mutations accumulate a vaccine that might not be showing antibody dependent enhancement might start showing enhancement of infection based on the mutations that emerge. Also, spike protein is heavily prone to mutations thus requiring next generation vaccines based on mutations that might lead to escape from neutralizing antibodies. In our invention we have targeted a non-structural protein (NSP3) for designing a mRNA based vaccine candidate. As this is based on a non-structural protein we do not anticipate antibody dependent enhancement of infection. We used the MacI domain of this protein. We have added a secretory signal to enable secretion of MacI so that all possible immunological pathways are stimulated. Mice based immunizations showed effective IgG production against MacI that also lasted for extended period time post prime boost immunization.
Resumen de: WO2026226718A2
Monoclonal antibodies and antigen binding fragments thereof are disclosed herein that specifically bind NRP1. Conjugates of these antibodies and antigen binding fragments are also disclosed. Further disclosed are chimeric antigen receptors (CARs) including a disclosed antibody or antigen binding fragment, and cells expressing such chimeric antigen receptors (e.g., CAR T cells), and pharmaceutical compositions including these CAR T cells. Multi-specific antibodies, nucleic acid molecules, vectors including these nucleic acid molecules, and pharmaceutical compositions including these compositions are also provided. Methods are also provided for detecting and/or treating a tumor that express NRP1 in a subject. Methods are further provided for treating a coronavirus infection, such as a SARS-CoV-2 infection, or an Epstein Barr virus (EBV) infection, in a subject.
Resumen de: EP4830786A2
0001 The present invention encompasses TLR7/8 antagonists for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
Resumen de: MX2026005520A
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
Resumen de: WO2026222087A2
The invention relates to saponin matrix adjuvants comprising Matrix-A and Matrix-C particles at fixed weight ratios between about 70:30 to 10:90 (Matrix-A:Matrix-C), specifically about 60:40, 59:41, 58:42, 57:43, 56:44, 55:45, 54:46, 53:47, 52:48, 51:49, or 50:50, in contrast to conventional 85:15 Matrix-M adjuvant. Matrix-A and Matrix-C are cage-like particles formed from chromatographically separated Quillaja saponin fractions with cholesterol and phosphatidylcholine. At the disclosed ratios, the compositions unexpectedly enhance lysosomal targeting, lysosomal membrane permeabilization, antigen cross-presentation, and activation of antigen-presenting cells, yielding at least about 30–100% higher frequencies of antigen-specific CD8 T cells producing IFN-γ under comparable dosing conditions. The saponin matrix compositions can be formulated with viral antigens (for example SARS-CoV-2 spike, RSV F0, PIV3, hMPV F) or tumor antigens (including defined tumor-associated antigens and neoantigens) to provide vaccines that induce protective antiviral immunity and therapeutic antitumor responses using manufacturing processes compatible with existing Matrix platforms.
Resumen de: WO2026222182A1
Disclosed herein is a library of SARS-CoV-2 PLpro inhibitors. The compounds described herein represent potent inhibitors of PLpro with activity translating to live virus assays in mammalian and human host cells. Also provided herein are methods of using the PLpro inhibitors for preventing or treating infections, diseases, and/or symptoms caused by exposure to a coronavirus, such as SARS-CoV-2, SARS-CoV-1, and MERS in a subject in need thereof.
Resumen de: WO2026220159A1
Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.
Resumen de: WO2026220162A1
The present invention relates to an antibody molecule or an antigen binding fragment, which targets a SARS-related coronavirus, for example SARS-CoV-2 and variants thereof, suitably which is bovine derived. The invention further relates to a method of producing these antibody molecules and/or antigen binding fragments, and the uses of these antibody molecules and/or antigen binding fragments. The invention also relates to nucleic acid molecules encoding the molecules and/or fragments, and expression vectors and hosts cells comprising the same.
Resumen de: US20260328766A1
Method and device for detecting SARS-CoV-2 specific T-Cell interferon-gamma activation is described. By using a microfluidic chip to allow ELISpot interferon gamma release assays (IGRA) be performed using a small amount of fingerstick whole blood sample, fast results can be provided with minimal amount of blood sample.
Resumen de: US20260325627A1
0000 Immunological inactive polyether polymers represented by the following formula I:
0000
0000 wherein at least 3% of the residues R include ethylene oxide side chains, oligo(ethylene oxide) side chains and/or glycerol ether side chains and at least 3% of the residues R are hydrogen and R may also be a C1 to C3-alkyloxymethyl side chain. Further, a process for the preparation of the polymers. Finally, the use of the polymers for the preparation of conjugates, especially bioconjugates and the conjugates themselves as alternative for PEGylated therapeutics. The conjugates may include bioactive compounds and/or lipids. They are especially useful for the preparation of vaccines, lipid particles, especially lipid nanoparticles and may be used for the preparation of vaccines against COVID-19.
Resumen de: US20260325625A1
0000 Recombinant murine pneumonia viruses (rMPV) expressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and their use as live-attenuated virus vaccines against SARS-CoV-2 are described. The rMPV expressing S protein are safe, immunogenic, and efficacious for protecting a subject against SARS-CoV-2 infection and disease, as demonstrated in a non-human primate model. The rMPV induce a strong systemic and mucosal antibody response against the SARS-CoV-2 S protein. Furthermore, a single dose of the live-attenuated rMPV induced strong protection against SARS-CoV-2 challenge, while two doses were fully protective.
Resumen de: US20260327279A1
0000 A HIP/PAP protein, or a derivative thereof, is provided for the treatment and prevention cognition conditions. In particular the HIP/PAP protein, or a derivative thereof is for the treatment of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s). The HIP/PAP protein, or a derivative thereof is also alleviating cognitive deficit in an individual affected by a disorder selected from Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
Resumen de: US20260327238A1
The present invention provides a compound useful for the treatment or prevention of SARS-CoV-2 novel coronavirus infection.The present invention relates to a compound represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:wherein ring A, R1 and R7, R2 and R4, X and Y, as well as Z are according to the definitions as described in the specification;use thereof for the treatment or prevention of SARS-CoV-2 novel coronavirus infection; and pharmaceutical compositions comprising the same.
Nº publicación: US20260325553A1 22/10/2026
Solicitante:
PAXTON PIERSON SUZANNE J [US]
Paxton-Pierson Suzanne J.
Resumen de: US20260325553A1
0000 Methods and compositions to lessen toxicities in COV19 vaccine aftermath. These involve administering synergistic or complementary formulations of early detoxification agents, antioxidants, anti-inflammatories, pro-immunity agents, gp41/gp120 inhibitors, nAChR/NAD<+>, boosters, ACE-2 modulators, anticoagulants and other micronutrients, vitamins, plant-derived compounds and selections from pertinent, major drug classes. tailored to address post-vaccination complications effectively.
BOPI
Sede Electrónica
